摘要
免疫检查点抑制剂(immune checkpoint inhibitor,ICI)通过激活人体对癌细胞的免疫反应,彻底改变了多种癌症的治疗策略,包括多种消化道肿瘤。然而,ICI导致的不良反应累及多器官和系统,威胁抗肿瘤疗效带来的生存获益。《中国消化道肿瘤免疫治疗不良反应专家共识(2023年版)》聚焦于消化道肿瘤,针对消化道肿瘤不同免疫联合治疗模式相关不良反应以及消化道肿瘤常见免疫相关不良事件的临床诊疗提供管理建议。
Immune checkpoint inhibitor(ICI)have revolutionized the treatment strategies for various cancers,including gastrointestinal system tumor,by activating the immune response to cancer cells.However,the adverse events caused by ICI involve multiple organs,threatening the survival benefits against anti-tumor efficacy.Consensus on immune related adverse events of gastrointestinal tumor in China(2023 edition)management recommendations for the clinical diagnosis and treatment of adverse events related to different combined immunotherapy of gastrointestinal tumor and common immune-related adverse events in gastrointestinal tumor.
出处
《肿瘤综合治疗电子杂志》
2023年第2期26-60,共35页
Journal of Multidisciplinary Cancer Management(Electronic Version)
关键词
免疫检查点抑制剂
免疫相关不良事件
消化道肿瘤
免疫联合治疗
Immune checkpoint inhibitor
Immune-related adverse events
Gastrointestinal tumor
Combined immunotherapy
